CTOs on the Move

Norbrook

www.norbrook.com

 
Norbrook® is a true innovator and dedicated to novel research and revolutionary processes and products. Lord Ballyedmond, Founder, Chairman and CEO of the Norbrook Group began his career in the pharmaceutical industry in the USA in the 1960s and now controls the largest privately owned pharmaceutical company in the world.    The company is very active in both medical and veterinary products.    Research and Development is the key to Norbrook`s success with the R&D Department central to the company`s structure. It is responsible for new product development, technical support and meeting regulatory and licensing protocols. Norbrook invests more than 10% of its turnover ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $50-100 Million
  • www.norbrook.com
  • 9733 Loiret Boulevard
    Lenexa, KS USA 66219
  • Phone: 913.599.5777

Executives

Name Title Contact Details

Similar Companies

Pharm-Olam

Pharm-Olam International is a multi-national contract research organization (CRO) offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.

Ridgeview Behavioral Health Services

Ridgeview’s earliest beginnings date back to 1954 when at the suggestion of the Oak Ridge schools’ Pupil Personnel Department, under the leadership of Ms.Sarah Ketron, a group of Oak Ridge and Anderson County citizens met to consider forming a mental h...

Canadian Phamacy Online

Canadian Phamacy Online is a Winnipeg, MB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Harsha Behavioral Center

Harsha Behavioral Center is a freestanding acute psychiatric care hospital serving children, adolescents, adults, and geriatrics in the Wabash Valley, Vigo County area in and around Terre Haute, Indiana. Harsha Center, Paras Harshawat M.D.

Esperance Pharmaceuticals

Esperance Pharmaceuticals, Inc. is developing a new class of targeted oncology products that selectively kill cancer cells without harming normal cells. Targeting occurs through binding to specific receptors on the cancer cell surface. The novel product candidates destroy dividing and non-dividing cancer cells including those known to be resistant to chemotherapeutics.